Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q1 2021 Earnings Presentation
14 slides from Harmony Biosciences's earnings presentation, May 11, 2021
Slide 1: Q1 2021 Financial and Business Update
Exhibit 99.2 Harmony Biosciences Q1 2021 Financial and Business Update May 11, 2021Exhibit 99.2 Harmony Biosciences Q1 2021 Financial and Business Update May 11, 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc
Slide 3: Harmony's Strategy for Growth
Harmony’s Strategy for Growth Expand Optimize Acquire ® WAKIX Clinical New Commercial Utility of Assets Launch WAKIX 3Harmony’s Strategy for Growth Expand Optimize Acquire ® WAKIX Clinical New Commercial Utility of Assets Launch WAKIX 3
Slide 4: Q1 2021 WAKIX Revenue Performance
Q1 2021 WAKIX Revenue Performance Continued Growth with Q1 Revenue of $59.7M 1Q21 1Q21 $59.7 $56.3 1Q20 4Q20 1Q21 vs. vs. 4Q20 1Q20 $45.6 $19.8 $56.3 $59.7 6% 201% $38.0 Strong Revenue Growth in Q1 2021 $19.8 ▪ Over 200% growth Q1 2021 vs. Q1 2020 ▪ Continued sequential quarter over $6.0 quarter gro
Slide 5: Driving Growth Through Our Launch For WAKIX
Driving Growth Through Our Launch For WAKIX Q1 2021 Performance ~2,800 Average # of Patient Outreach WAKIX Patients Programs & Support Expanded Virtual Engagement Programs Unique HCP Prescribers >2,700 Since Launch Healthcare Professional Educational Initiatives U.S. Covered Lives With Formulary Acc
Slide 6: Core Attributes of WAKIX Product Profile Align with Existing Unmet Needs in Narcolepsy
Core Attributes of WAKIX Product Profile Align with Existing Unmet Needs in Narcolepsy Top Unmet Needs in Narcolepsy * WAKIX (pitolisant) (cited by patients and HCPs) Need for non-scheduled treatment options First and only FDA approved (low/no abuse potential) non-scheduled treatment option for narc
Slide 7: HCP Insights Demonstrate Future Growth Opportunity for WAKIX in Adult Narcolepsy
HCP Insights Demonstrate Future Growth Opportunity for WAKIX in Adult Narcolepsy Key Findings from HCP Market Research: 95% ~90% 84% Significant unmet need WAKIX is effective for Expecting to prescribe the and WAKIX offers a treatment of EDS and same or increase their unique treatment option 90% eff
Slide 8: Patient Insights Demonstrate Future Growth Opportunity for WAKIX
Patient Insights Demonstrate Future Growth Opportunity for WAKIX Key Findings from Patient Market Research: ▪ Patients communicated an overall good experience with WAKIX ▪ Better experience in learning about and accessing the medication than other narcolepsy treatments 80% 90% 75% Patient’s interest
Slide 9: Multiple Opportunities for Pitolisant
Multiple Opportunities for Pitolisant 9Multiple Opportunities for Pitolisant 9
Slide 10: WAKIX: Effective in Patients with High Burden of Narcolepsy Symptoms
WAKIX: Effective in Patients with High Burden of Narcolepsy Symptoms ¾ Post-hoc analyses of pooled data from pivotal randomized controlled trials (HARMONY 1 and HARMONY CTP) ¾ Assessed response to WAKIX compared to placebo in patients who had a high burden of EDS (ESS ≥ 16) or cataplexy (weekly rate
Slide 11: WAKIX: Onset of Effect Beginning at Week 2
WAKIX: Onset of Effect Beginning at Week 2 ¾ Post-hoc analyses of pooled data from pivotal randomized controlled trials (HARMONY 1 and HARMONY CTP) ¾ Assessed time-to-onset of response for WAKIX compared to placebo from baseline to end of trial Conclusions: ¾ WAKIX was effective for improvement in E
Slide 12: Q1 2021 Financial Summary
Q1 2021 Financial Summary (in millions, USD) Three Months Ended March 31, 2021 2020 Net Product Revenues $ 59.7 $ 19.8 Cost of Product Sold 10.4 3.5 Total Operating Expenses $ 34.7 $ 26.0 R&D Expense 4.7 3.4 S&M Expense 15.5 13.3 G&A Expense 14.5 9.3 Net Income (Loss) $ 7.4 $ (38.6) Cash & cash equi
Slide 13: GAAP vs Non-GAAP Reconciliation
GAAP vs Non-GAAP Reconciliation (in millions, USD) Three Months Ended March 31, 2021 2020 GAAP reported net income (loss) $ 7.4 $ (38.6) Interest expense / income 7.1 6.4 Taxes Depreciation 0.1 0.1 Amortization 4.6 1.8 EBITDA 19.2 (30.4) Stock-based compensation expense 3.3 0.4 Loss on debt extingui
Slide 14: Thank You
Thank You May 11, 2021Thank You May 11, 2021
Harmony Biosciences Holdings — Q1 2021 Earnings Presentation on 6ix